Establishing anchor-based minimally important differences for the EORTC QLQ-C30 in glioma patients.
Linda DirvenJammbe Z MusoroCorneel CoensJaap C ReijneveldMartin J B TaphoornFlorien W BoeleMogens GroenvoldMartin J van den BentRoger StuppGalina VelikovaKim CocksMirjam A G SprangersMadeleine T KingHans-Henning FlechtnerAndrew BottomleyPublished in: Neuro-oncology (2021)
MIDs for the EORTC QLQ-C30 scales generally ranged between 4 and 11 points for both within-group mean change and between-group mean difference in change. These results can be used to interpret QLQ-C30 results from glioma trials.